Covered recipient · General Payments record
EVANTHIA GALANIS
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$20,258.52
8 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $10,800.00 | 2 |
| Travel and Lodging | $9,305.36 | 3 |
| Food and Beverage | $153.16 | 3 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim International GmbH | $18,258.52 | 7 |
| Merck Sharp & Dohme LLC | $2,000.00 | 1 |
Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EVANTHIA GALANIS
NPI 1326028234 · CMS profile ID 286517
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
ROCHESTER, MN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
8 matching records · $20,258.52 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–8 of 8.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,000.00 | 12/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141552268 | CMS |
| Boehringer Ingelheim International GmbH | $8,800.00 | 04/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155218132 | CMS |
| Boehringer Ingelheim International GmbH | $371.79 | 04/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155218134 | CMS |
| Boehringer Ingelheim International GmbH | $31.08 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963294 | CMS |
| Boehringer Ingelheim International GmbH | $51.18 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963296 | CMS |
| Boehringer Ingelheim International GmbH | $70.90 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963298 | CMS |
| Boehringer Ingelheim International GmbH | $376.02 | 02/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963300 | CMS |
| Boehringer Ingelheim International GmbH | $8,557.55 | 02/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963302 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2024
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2020 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $59,021,227.49 | 388 |
| PY2024 | Principal investigator | $12,702,832.22 | 309 |
| PY2023 | Principal investigator | $371,957.47 | 19 |
| PY2022 | Principal investigator | $13,006.11 | 2 |
| PY2021 | Principal investigator | $94,282.54 | 7 |
| PY2020 | Principal investigator | $16,250.00 | 1 |
| PY2019 | Principal investigator | $20,000.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
388 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $85,644.72 | 12/22/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS | WI208323 PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN A CONJUGATED ANTICD22 MONOCLONAL ANTIBODY TO FRONTLINE THERAPY IN YOUNG ADULTS AGES 1639 YEARS WITH NEWLY DIAGNOSED PRECURSOR BCELL ALL | No dispute reported | 06/30/2026 | 1228721281 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 11/28/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971297 |
| Principal investigator 1 | Janssen Research & Development, LLC | $161,501.41 | 11/24/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS IN ONC | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) forMetastaticProstateCancer, ASPIRE Trial | No dispute reported | 06/30/2026 | 1175302868 |
| Principal investigator 1 | SERVIER PHARMACEUTICALS LLC | $403,309.28 | 11/15/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION | Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs. Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas | No dispute reported | 06/30/2026 | 1235967387 |
| Principal investigator 1 | SERVIER PHARMACEUTICALS LLC | $40,798,260.00 | 11/05/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION | Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs. Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas | No dispute reported | 06/30/2026 | 1235967383 |
| Principal investigator 1 | SERVIER PHARMACEUTICALS LLC | $4,079,826.00 | 11/05/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION | Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs. Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas | No dispute reported | 06/30/2026 | 1235967385 |
| Principal investigator 1 | PFIZER INC. | $572,700.00 | 10/13/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | WI208323 PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN A CONJUGATED ANTICD22 MONOCLONAL ANTIBODY TO FRONTLINE THERAPY IN YOUNG ADULTS AGES 1639 YEARS WITH NEWLY DIAGNOSED PRECURSOR BCELL ALL | No dispute reported | 06/30/2026 | 1228814041 |
| Principal investigator 1 | PFIZER INC. | $572,700.00 | 10/13/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | WI208323 PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN A CONJUGATED ANTICD22 MONOCLONAL ANTIBODY TO FRONTLINE THERAPY IN YOUNG ADULTS AGES 1639 YEARS WITH NEWLY DIAGNOSED PRECURSOR BCELL ALL | No dispute reported | 06/30/2026 | 1228814046 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $576,486.81 | 10/11/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1185537345 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 10/02/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971293 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379550 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379552 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379554 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379556 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379558 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379560 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379562 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 09/30/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,760.52 | 09/29/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377015 |
| Principal investigator 1 | Janssen Research & Development, LLC | $552.49 | 09/29/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377023 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,533.69 | 09/29/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377095 |
| Principal investigator 1 | Servier BioInnovation | $5,500.00 | 09/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971249 |
| Principal investigator 1 | Servier BioInnovation | $1,500.00 | 09/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971252 |
| Principal investigator 1 | Servier BioInnovation | $450.00 | 09/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971257 |
| Principal investigator 1 | Servier BioInnovation | $1,250.00 | 09/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971261 |
| Principal investigator 1 | Servier BioInnovation | $586.00 | 09/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971265 |
| Principal investigator 1 | Servier BioInnovation | $250.00 | 09/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971269 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 09/03/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971240 |
| Principal investigator 1 | Servier BioInnovation | $2,003.00 | 09/03/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971245 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 08/25/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228840493 |
| Principal investigator 1 | Servier BioInnovation | $1,875.00 | 08/22/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971289 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $429,466.00 | 08/21/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1185537343 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 08/18/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228840512 |
| Principal investigator 1 | PFIZER INC. | $50,944.32 | 08/11/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228834440 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,230.75 | 07/29/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION | A RANDOMIZED PHASE II TRIAL WITH A SAFETY LEAD IN TO EVALUATE PALBOCICIB VS PALBOCICIB CEMIPLIMAB FOR THE TREATMENT OF ADVANCED DEDIFFERENTIATED LIPOSARCOMA | No dispute reported | 06/30/2026 | 1184221352 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 07/29/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971281 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 07/14/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228842067 |
| Principal investigator 1 | Servier BioInnovation | $1,500.00 | 07/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971273 |
| Principal investigator 1 | Servier BioInnovation | $1,250.00 | 07/11/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971278 |
| Principal investigator 1 | Servier BioInnovation | $2,003.00 | 06/27/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971233 |
| Principal investigator 1 | PFIZER INC. | $9,511.47 | 06/16/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228845168 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 06/16/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971228 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 06/16/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971236 |
| Principal investigator 1 | Genentech, Inc. | $39,366.60 | 05/29/2025 | Non-covered Recipient Entity ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN | AFT57 Induction and adjuvant atezolizumab with or without tiragolumab in stage III NSCLC Randomize | No dispute reported | 06/30/2026 | 1211571718 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $746,740.00 | 05/15/2025 | Non-covered Recipient Entity MEMORIAL SLOAN KETTERING NASSAU | RANDOMIZED PHASE II STUDY OF SORAFENIB and or EVEROLIMUS IN PATIENTS WITH RADIOACTIVE IODINE REFRACTORY HuRTHLE CELL THYROID CANCER | No dispute reported | 06/30/2026 | 1190310104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $576,321.37 | 05/12/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377060 |
| Principal investigator 1 | PFIZER INC. | $9,511.47 | 05/12/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228856296 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 05/05/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228851420 |
| Principal investigator 1 | PFIZER INC. | $9,511.47 | 04/29/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228854991 |
| Principal investigator 1 | Genentech, Inc. | $255,758.02 | 04/28/2025 | Non-covered Recipient Entity ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN | A PHASE IB II UMBRELLA STUDY OF TARGETED AGENTS WITH ATEZOLIZUMAB FOR PATIENTS WITH RECURRENT OR PER | No dispute reported | 06/30/2026 | 1211571711 |
| Principal investigator 1 | PFIZER INC. | $194,866.00 | 04/18/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS | A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 | No dispute reported | 06/30/2026 | 1228850467 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,350.33 | 04/14/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,471.95 | 04/14/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377069 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,807.49 | 04/14/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377076 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 04/14/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228854999 |
| Principal investigator 1 | PFIZER INC. | $4,295,583.47 | 03/31/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228855039 |
| Principal investigator 1 | Servier BioInnovation | $2,003.00 | 03/31/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971224 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 03/14/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971215 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 03/14/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971220 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,688.55 | 03/05/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION | ALLIANCE A061202 A PHASE I/II STUDY OF POMALIDOMIDE, DEXAMETHASONE AND MLN9708 VS. POMALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA REFRACTORY TO LENALIDOMIDE AND PROTEASOME INHIBITOR-BASED THERAPY | No dispute reported | 06/30/2026 | 1235957764 |
| Principal investigator 1 | PFIZER INC. | $50,944.32 | 02/10/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228855031 |
| Principal investigator 1 | Genentech, Inc. | $1,024,222.03 | 02/07/2025 | Non-covered Recipient Entity ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN | FOLFOX Alone or Combined with a PD L1 | No dispute reported | 06/30/2026 | 1211571726 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378922 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378924 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378926 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378928 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378930 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378932 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378934 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378936 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378938 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378940 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378942 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378944 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378946 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378948 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378950 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378952 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378954 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378956 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378958 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378960 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378962 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378964 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378966 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378968 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378970 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378972 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378974 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378976 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378978 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378980 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378982 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378984 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378986 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378988 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378990 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378992 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378994 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378996 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222378998 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379000 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379002 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379004 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379006 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379008 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379010 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379012 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379014 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379016 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379018 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379020 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379022 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379024 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379026 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379028 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379030 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379032 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379034 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379036 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379038 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379040 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379042 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379044 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379046 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379048 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379050 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379052 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379054 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379056 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379058 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379060 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379062 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379064 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379066 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379068 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379070 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379072 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379074 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379076 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379078 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379080 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379082 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379084 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379086 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379088 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379090 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379092 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379094 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379096 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379098 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379100 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379102 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379104 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379106 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379108 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379110 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379112 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379114 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379116 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379118 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379120 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379122 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379124 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379126 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379128 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379130 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379132 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379134 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379136 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379138 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379140 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379142 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379144 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379146 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379148 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379150 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379152 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379154 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379156 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379158 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379160 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379162 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379164 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379166 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379168 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379170 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379172 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379174 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379176 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379178 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379180 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379182 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379184 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379186 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379188 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379190 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379192 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379194 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379196 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379198 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379200 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379202 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379204 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379206 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379208 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379210 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379212 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379214 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379216 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379218 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379220 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379222 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379224 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379226 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379228 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379230 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379232 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379234 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379236 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379238 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379240 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379242 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379244 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379246 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379248 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379250 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379252 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379254 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379256 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379258 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379260 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379262 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379264 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379266 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379268 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379270 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379272 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379274 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379276 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379278 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379280 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379282 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379284 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379286 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379288 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379290 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379292 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379294 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379296 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379298 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379300 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379302 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379304 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379306 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379308 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379310 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379312 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma | No dispute reported | 06/30/2026 | 1222379314 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379316 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379318 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379320 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379322 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379324 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379326 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379328 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379330 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379332 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379334 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379336 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379338 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379340 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379342 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379344 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379346 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379348 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379350 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379352 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379354 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379356 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379358 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379360 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379362 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379364 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379366 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379368 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379370 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379372 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379374 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379376 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379378 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379380 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379382 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379384 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379386 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379388 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379390 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379392 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379394 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379396 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379398 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379400 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379402 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379404 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379406 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379408 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379410 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379412 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379414 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379416 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379418 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379420 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379422 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379424 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379426 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379428 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379430 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379432 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379434 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379436 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379438 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379440 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379442 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379444 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379446 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379448 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379450 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379452 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379454 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379456 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379458 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379460 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379462 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379464 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379466 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379468 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379470 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379472 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379474 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379476 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379478 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379480 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379482 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379484 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379486 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379488 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379490 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379492 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379494 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | No dispute reported | 06/30/2026 | 1222379496 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379498 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379500 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379502 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379504 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379506 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379508 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379510 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379512 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379514 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379516 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379518 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379520 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379522 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379524 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379526 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379528 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379530 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379532 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379534 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379536 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379538 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379540 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379542 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379544 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379546 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Alliance for Clinical Trials in Oncology Foundation | Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) | No dispute reported | 06/30/2026 | 1222379548 |
| Principal investigator 1 | Genentech, Inc. | $1,911.00 | 01/30/2025 | Non-covered Recipient Entity ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN | AFT57 Induction and adjuvant atezolizumab with or without tiragolumab in stage III NSCLC Randomize | No dispute reported | 06/30/2026 | 1211571714 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 01/17/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971157 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 01/17/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971162 |
| Principal investigator 1 | Servier BioInnovation | $2,003.00 | 01/17/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971166 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 01/17/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971183 |
| Principal investigator 1 | Servier BioInnovation | $1,579.00 | 01/17/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971195 |
| Principal investigator 1 | Servier BioInnovation | $2,003.00 | 01/17/2025 | Non-covered Recipient Entity MAYO CLINIC JACKSONVILLE | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235971207 |
| Principal investigator 1 | PFIZER INC. | $2,162,820.08 | 01/13/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228855007 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 01/13/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228860723 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 01/13/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228860731 |
| Principal investigator 1 | PFIZER INC. | $161,993.33 | 01/13/2025 | Non-covered Recipient Entity ALLIANCE FOUNDATION TRIALS LLC | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228860737 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $370,087.24 | 01/07/2025 | Non-covered Recipient Entity MEMORIAL SLOAN KETTERING CANCER CENTER | RANDOMIZED PHASE II STUDY OF SORAFENIB and or EVEROLIMUS IN PATIENTS WITH RADIOACTIVE IODINE REFRACTORY HuRTHLE CELL THYROID CANCER | No dispute reported | 06/30/2026 | 1190313455 |